Navigation Links
Cephalon Quarterly Conference Call Invitation
Date:3/31/2009

First Quarter 2009 Earnings Conference Call Tuesday, May 5, 2009, 5:00 p.m. U.S. EDT

FRAZER, Pa., March 31 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) has scheduled its regular quarterly earnings conference call covering first quarter 2009 results for 5:00 p.m. EDT on Tuesday, May 5, 2009.

May 5, 2009 Schedule

4:10 p.m. EDT -- Q1 2009 results will be distributed by PRNewswire

4:50 p.m. EDT -- To participate in the conference call, dial 913-312-1232 and refer to Conference Code Number 9819274

5:00 p.m. EDT -- Conference call begins promptly.

Simultaneous Webcast

Investors can listen to the call live by logging on to the company's website at www.cephalon.com and clicking on "Investors," then "Webcast." Please click on the link and follow the prompts for registration and access.

If you are unable to listen to the live broadcast, an audio or webcast replay of the call will be available approximately two hours after the event until 8:00 p.m. EDT, May 12, 2009. To listen to the audio replay, dial 719-457-0820 and use the Conference Code Number 9819274.

Additional information presented on the conference call may be made available on the Investors page of the company's website.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
2. Cephalon Quarterly Conference Call Invitation
3. Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference
4. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
5. Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
6. Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Ohio Sales Reps Information Launched Massive Government Investigation of Cephalon
8. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
9. Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA
10. Cephalon Conference Call Invitation
11. Cephalon Reports Strong First Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... PITTSBURGH, PA (PRWEB) , ... December 09, 2016 , ... ... treatments," said an inventor from Winchester, Va. "I thought that if the nebulizer had ... their treatments rather than fearing them." , He developed the patent-pending NEBY to avoid ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Medical Center has been recognized for adherence to the highest standards of ... medical accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... -- Research and Markets has announced the addition of ... Type, Application, Usability - Forecast to 2025" report to their ... , , ... to grow at a CAGR of around 3.2% from 2015 to ... include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in ...
(Date:12/8/2016)...   TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...
Breaking Medicine Technology: